A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia

Completed · Phase 1/Phase 2

Conditions studied: Acute Leukemia

In brief

A phase I-II open label study of PTX-200 in combination with cytarabine in the treatment of relapsed or refractory acute leukemia.

Key facts

Study ID

NCT02930109

Run by

Prescient Therapeutics, Ltd.

People needed

33

Starts

2016-12-09

Expected to finish

2024-03-04

Last updated by the study team

2024-04-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathologic confirmation of the diagnosis of AML, ALL (acute lymphoblastic leukemia), or blast-phase CML (chronic myelogenous leukemia)
• Age ≥ 18 years
• ECOG Performance Status 0-2
• Patients must be able to give adequate informed consent

You may not qualify if…

• Hyperleukocytosis with ≥ 30,000 leukemic blasts/µL blood (hydroxyurea permitted up to 24 hours prior to beginning study drugs)
• Uncontrolled Disseminated Intravascular Coagulation (DIC)
• Uncontrolled diabetes mellitus
• Active, uncontrolled infection

Where it is running

• Moffitt Cancer Center — Tampa, Florida, United States
• University of Kansas Cancer Center — Fairway, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.